Controlling Rapid Atrial Fibrillation With Dexmedetomidine

• Status: Unknown status
• Trial end date: 2020-06-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study comparing the addition of Dex or placebo to standard of care (SOC) treatment.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stony Brook University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Adult patients in a SBU Hospital ICU with rapid-AF (with ventricular rates >100 bpm).

• Patient screening will be conducted prior to patient or LAR consent.

Exclusion Criteria:

• Patients age <18yrs;

• Anticipated ICU stay <11hrs;

• Permanently paced heart rhythm;

• Known 2nd or 3rd degree heart block;

• Junctional rhythms;

• Known pregnancy;

• Known allergy to Dexmedetomidine;

• Receiving Dexmedetomidine prior to study onset;

• Non-intubated patients w/ Glasgow Coma Scale <8;

• Weight >400lbs (protocol dosing restriction);

• Untreated, symptomatic hypotension (SBP<90mmHg);

• Received amiodarone, lidocaine, or mexileine w/in 4hrs prior to consent.